Eisai Co Ltd Spons A (ESALY) 41.9100 $ESALY
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S.
JCN Newswire - Wed Aug 20, 1:21AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa (generic name: perampanel) as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC).
Eisai Supports Earthquake Relief Efforts in Yunnan, China
JCN Newswire - Wed Aug 06, 8:51PM CDT
Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China.
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
JCN Newswire - Wed Jul 30, 9:48PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate ("lenvatinib" in the treatment of radioiodine-refractory differentiated thyroid cancer.
Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy
JCN Newswire - Thu Jul 03, 7:58PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments.
Eisai to Launch First Chocola BB Brand Product "Chocola BB Royal Drink" in China
JCN Newswire - Wed Jul 02, 5:46AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai" announced today that it has launched its Chocola BB Royal Drink in China. This marks the first Chocola BB series product launched in China by Eisai.
Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in
George Budwell, The Motley Fool - Motley Fool - Fri Feb 14, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Can These Obesity Drug Stocks Bounce Back in 2014?
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 1:34PM CST
Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as...
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S.
JCN Newswire - Wed Aug 20, 1:21AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the indication expansion of its in-house developed antiepileptic drug Fycompa (generic name: perampanel) as an adjunctive treatment of primary generalized tonic-clonic seizures (PGTC). Eisai Supports Earthquake Relief Efforts in Yunnan, China
JCN Newswire - Wed Aug 06, 8:51PM CDT
Eisai expresses its heartfelt sympathies to all those affected by the recent earthquake which occurred in Ludian county of Zhaotong city, Yunnan province, China.
Arena Pharmaceuticals Falls on Wider-than-Expected Q2 Loss - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Aug 04, 10:10AM CDT
Arena Pharmaceuticals, Inc. (ARNA) reported a net loss (excluding one-time items) of 12 cents per share in the second quarter of 2014.
EMA Grants Eisai's Anticancer Agent Lenvatinib Request for Accelerated Assessment
JCN Newswire - Wed Jul 30, 9:48PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that its U.K. subsidiary Eisai Europe Ltd. has been granted an accelerated review by the European Medicines Agency (EMA) for its in-house developed anticancer agent lenvatinib mesylate ("lenvatinib" in the treatment of radioiodine-refractory differentiated thyroid cancer. Arena Pharmaceuticals-Eisai Boost Obesity Drug Sales Force - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jul 11, 3:45PM CDT
Arena Pharmaceuticals, Inc. (ARNA) announced that partner Eisai Inc. (ESALY) has increased the sales force of Belviq.
Eisai Receives European Commission Approval of Indication Expansion for Anticancer Agent Halaven for Advanced Breast Cancer After Only One Prior Chemotherapy
JCN Newswire - Thu Jul 03, 7:58PM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin" to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting, unless patients were not suitable for these treatments. Eisai to Launch First Chocola BB Brand Product "Chocola BB Royal Drink" in China
JCN Newswire - Wed Jul 02, 5:46AM CDT
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"
announced today that it has launched its Chocola BB Royal Drink in China. This marks the first Chocola BB series product launched in China by Eisai. Does Arena Pharmaceuticals Have An Anti-Smoking Opportunity?
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Drugs that go on to garner the coveted blockbuster status, or $1 billion in annual sales, are often able to do so by being used for multiple indications. This can be achieved through either a formal label expansion process involving clinical trials...
Ironwood Initiates GERD Study, Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 2:25PM CDT
Ironwood Pharmaceuticals announced the initiation of a phase IIa study on its gastroesophageal reflux disease candidate, IW-3718.
Biogen, Eisai Join Up in Alzheimer's Drug Pact
Ben Fidler, The Motley Fool - Motley Fool - Thu Mar 06, 5:30PM CST
Biogen Idec may be best known for its multiple sclerosis drugs, but the biotech giant is also giving itself a few more chances to succeed in the high-risk field of Alzheimer's disease therapies. Cambridge, Mass.-based Biogen today cut a...
Biogen-Eisai Ink Alzheimer's Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 3:45PM CST
Biogen Idec and Eisai announced a development and commercialization agreement for a couple of Alzheimer's disease candidates in Eisai's pipeline.
Today’s Top Biotech Stories: Xoma, Biogen, Agenus, and GSK
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 05, 8:01AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four stocks that could make health care...
Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 04, 1:05PM CST
On paper, it just makes so much sense that physicians and patients would turn to chronic weight control management therapies offered by VIVUS and Arena Pharmaceuticals as in addition to proper diet and exercise to lose weight. But paper is...
Arena Posts Wider Loss, Misses Ests - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 11:20AM CST
Arena Pharmaceuticals reported net loss per share of 11 cents in the fourth quarter of 2013.
Biotech Showdown: Arena Pharmaceuticals vs. VIVUS Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Feb 20, 8:59AM CST
The obesity-drug space is turning out to be tough sledding for Arena Pharmaceuticals and VIVUS , with both of their respective FDA approved medications failing to meet market expectations in terms of prescription numbers. As a result, shares of...
Arena Pharmarceuticals and Chelsea Therapeutics International Ltd Could Be Today's Biggest Movers in
George Budwell, The Motley Fool - Motley Fool - Fri Feb 14, 8:15AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Eisai Announces Launch of Pariet(R) Triple Formulation Combination Packs Rabecure(R) 400 and 800 and Rabefine(R), for Primary and Secondary H.Pyloei Eradication Respectively, in Japan
JCN Newswire - Wed Feb 12, 11:09PM CST
Eisai Co., Ltd. announced today that it will launch two types of triple formulation combination packs that contain its proton pump inhibitor Pariet(R) (rabeprazole sodium) in Japan on February 14 for use in Helicobacter pylori eradication.
Can These Obesity Drug Stocks Bounce Back in 2014?
Leo Sun, The Motley Fool - Motley Fool - Wed Feb 12, 1:34PM CST
Here's some good news -- America isn't the most obese nation in the world. The bad news is that America still ranks second behind Mexico, according to a United Nations report last July. About 31.8% of American adults are still classified as...
Eisai Announces Launch of Vascular Embolization Device DC Bead(R) in Japan
JCN Newswire - Mon Feb 03, 1:19AM CST
Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.
Phase III Trial Shows Lenvatinib Meets Primary Endpoint of Progression Free Survival Benefit in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer
JCN Newswire - Mon Feb 03, 1:18AM CST
Eisai Co., Ltd. announced today that the Phase III SELECT trial (Study 303) of lenvatinib, an investigational selective tyrosine kinase inhibitor (TKI) with a novel binding mode, the first-in-class of its kind, met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC).
